Samsung Biologics to build new plant in Incheon
- 4 years ago
삼성바이오로직스, 송도에 4공장 신설… 2만7000명 일자리 창출
A biopharmaceutical unit of South Korea's largest conglomerate Samsung Group, Samsung Biologics, has unveiled plans to build a fourth plant in the country.
The 1-point-4 billion dollar plant to be built in Incheon, aimed at maximizing its operational efficiency and manufacturing capabilities, would give the firm more capacity than any other contract biopharmaceutical company in the world.
Kim Ji-yeon reports.
Samsung Biologics, Samsung Group's biopharmaceutical unit, has laid out plans to build its fourth plant in South Korea to meet rising orders.
It looks to begin construction of the one-point-five billion U.S. dollar plant in Incheon's Songdo District during the latter half of this year.
At 238-thousand square-meters, the new plant is larger than all three of Samsung Biologics' current plants put together.
The total size of the investment is more than the total amount invested in the company's previous three plants combined.
The new plant will bring Samsung Biologics' total bioreactor capacity to 620-thousand liters, making it the largest contract biopharmaceutical manufacturer in the world.
The plant will focus on cell line development... which is used for mass production of antibody drugs, and assembling parts for finished products and materials for clinical testing.
With this, Samsung Biologics hopes to seize some 30-percent of the global bio contract manufacturing market share.
The plant is expected to help create nearly 27-thousand jobs in total... and bring more than four-point-seven-billion dollars of economic benefits.
The company has inked a combined 850-million dollars worth of deals to manufacture products for major global pharmaceutical giants during the first half of this year.
Kim Ji-yeon, Arirang News.
A biopharmaceutical unit of South Korea's largest conglomerate Samsung Group, Samsung Biologics, has unveiled plans to build a fourth plant in the country.
The 1-point-4 billion dollar plant to be built in Incheon, aimed at maximizing its operational efficiency and manufacturing capabilities, would give the firm more capacity than any other contract biopharmaceutical company in the world.
Kim Ji-yeon reports.
Samsung Biologics, Samsung Group's biopharmaceutical unit, has laid out plans to build its fourth plant in South Korea to meet rising orders.
It looks to begin construction of the one-point-five billion U.S. dollar plant in Incheon's Songdo District during the latter half of this year.
At 238-thousand square-meters, the new plant is larger than all three of Samsung Biologics' current plants put together.
The total size of the investment is more than the total amount invested in the company's previous three plants combined.
The new plant will bring Samsung Biologics' total bioreactor capacity to 620-thousand liters, making it the largest contract biopharmaceutical manufacturer in the world.
The plant will focus on cell line development... which is used for mass production of antibody drugs, and assembling parts for finished products and materials for clinical testing.
With this, Samsung Biologics hopes to seize some 30-percent of the global bio contract manufacturing market share.
The plant is expected to help create nearly 27-thousand jobs in total... and bring more than four-point-seven-billion dollars of economic benefits.
The company has inked a combined 850-million dollars worth of deals to manufacture products for major global pharmaceutical giants during the first half of this year.
Kim Ji-yeon, Arirang News.